中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

72 records (took 0.051 seconds)

    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
    22.
    发明申请
    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME 审中-公开

    公开(公告)号：US20190284276A1

    公开(公告)日：2019-09-19

    申请号：US16402829

    申请日：2019-05-03

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Leonie ALTEN ,  Dominik MAURER ,  Steffen WALTER ,  Sebastian BUNK

    IPC: C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  C07K16/18 ,  C07K14/725 ,  C07K14/78

    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
    23.
    发明申请
    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME 审中-公开

    公开(公告)号：US20180319884A1

    公开(公告)日：2018-11-08

    申请号：US16035300

    申请日：2018-07-13

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Leonie ALTEN ,  Dominik MAURER ,  Steffen WALTER ,  Sebastian BUNK

    IPC: C07K16/28 ,  C07K14/78 ,  C07K14/725 ,  A61P35/00 ,  C07K16/18 ,  A61K39/00

    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

    PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS
    27.
    发明申请
    PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS 审中-公开
    个性化免疫治疗几种神经和脑肿瘤

    公开(公告)号：US20150125477A1

    公开(公告)日：2015-05-07

    申请号：US14531472

    申请日：2014-11-03

    Applicant: IMMATICS BIOTECHNOLOGIES GMBH

    Inventor： Sabrina KUTTRUFF-COQUI ,  Toni WEINSCHENK ,  Jens FRITSCHE ,  Steffen WALTER ,  Norbert HILF ,  Oliver SCHOOR ,  Colette SONG ,  Harpreet SINGH

    IPC: A61K39/00 ,  C07K7/08 ,  C12Q1/68 ,  A61K35/14 ,  C07K16/28 ,  C07K7/06 ,  C07K14/74

    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

    Abstract translation: 本发明涉及用于免疫治疗方法的肽，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及肿瘤相关的细胞毒性T细胞（CTL）肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽的组合。 本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的HLA I类和II类分子的肽序列及其变体。

    IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER
    28.
    发明申请
    IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER 有权

    公开(公告)号：US20250066422A1

    公开(公告)日：2025-02-27

    申请号：US18936387

    申请日：2024-11-04

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Toni WEINSCHENK ,  Steffen WALTER ,  Jens FRITSCHE ,  Colette SONG ,  Harpreet SINGH

    IPC: C07K7/08 ,  A61K35/17 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/06 ,  C07K14/725 ,  C12N5/0783 ,  C12N9/64

    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.

    SELECTION OF IMMUNE CELLS USING PEPTIDE MHC COMPLEXES GENERATED BY CONDITIONAL LIGAND EXCHANGE
    29.
    发明公开
    SELECTION OF IMMUNE CELLS USING PEPTIDE MHC COMPLEXES GENERATED BY CONDITIONAL LIGAND EXCHANGE 审中-公开

    公开(公告)号：US20240358831A1

    公开(公告)日：2024-10-31

    申请号：US18685736

    申请日：2022-08-24

    Applicant: IMMATICS US, INC. ,  Immatics Biotechnologies GmbH

    Inventor： Stefanie SPALT ,  Claudia WAGNER ,  Dominik MAURER ,  Heiko SCHUSTER ,  Steffen WALTER

    IPC: A61K39/00 ,  C07K14/74 ,  C12N5/0783

    CPC classification number: A61K39/4632 ,  A61K39/4611 ,  C07K14/70539 ,  C12N5/0636 ,  C12N2502/11

    Abstract: The present invention relates to a method for selecting an immune cell expressing on its surface an antigen-binding protein specifically binding to a complex of a peptide A (PA) and a Major Histocompatibility Complex (MHC) molecule, comprising the steps of (i) providing a plurality of immune cells expressing different antigen-binding proteins; (ii) contacting the plurality of immune cells with a first composition comprising a complex 1A, comprising a MHC molecule 1 (M1) and a peptide A (PA), and a complex 1X, comprising M1 and a peptide B (PB); (iii) contacting the plurality of immune cells with a second composition comprising a complex 2A, comprising a MHC molecule 2 (M2) and PA, and a complex 2X, comprising M2 and a peptide C (PC); (iv) selecting from the plurality of immune cells a cell expressing an antigen binding protein that specifically binds to complex 1A, wherein complexes 1X and 2X, but not 1A and 2A, dissociate upon stimulation with a defined chemical or physical stimulus; and wherein the amino acid sequences of PB and PC differ in at least one amino acid. The invention further relates to an immune cell selected by the method according to the invention, a method of treatment using said immune cell, a kit for selecting a cell expressing on its surface an antigen-binding protein, and a peptide suitable for use in the method according to the invention.

Patent Agency Ranking